Clinical management in FNAIT - navigating a complicated landscape.

Area of Science:

• Perinatology
• Immunology
• Neonatology

Background:

• Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a leading cause of severe neonatal thrombocytopenia and intracranial hemorrhage (ICH) in newborns.
• Occurring in 0.5-1:1000 births, FNAIT arises from maternal antibodies targeting fetal platelets due to antigen incompatibility.
• The risk of ICH is a primary concern, with a reported incidence of 1:10,000, often occurring before birth.

Purpose of the Study:

• To review current antenatal and perinatal clinical management strategies for FNAIT.
• To discuss both screening and non-screening approaches for identifying and managing at-risk pregnancies.
• To explore expert opinions on a stratified approach to treatment during pregnancy.

Main Methods:

• This review synthesizes expert knowledge on FNAIT management.
• It addresses clinical scenarios with and without HPA-1a screening.
• Focus is on preventing fetal/neonatal ICH in subsequent pregnancies.

Main Results:

• FNAIT is often underdiagnosed due to a lack of routine antenatal HPA-1a screening.
• Current management for subsequent pregnancies focuses on preventing ICH, with treatment risk stratification being a key consideration.
• High-dose intravenous immunoglobulin (IVIg) is commonly used off-label, though a more selective approach is advocated.

Conclusions:

• Effective management of FNAIT requires careful consideration of screening and risk stratification.
• Preventing fetal ICH is the paramount goal in managing pregnancies at risk for FNAIT.
• Further research and consensus on stratified treatment protocols are needed for optimal patient outcomes.